HUTCHMED Announces Submission of US NDA for ORPATHYS® Plus TAGRISSO® in MET-Driven EGFR-Mutated ...

AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination - Regional Media News

Sept 29 (Reuters) - HUTCHMED (China) said on Tuesday that Anglo-Swedish drugmaker AstraZeneca had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer. ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and [...]

AstraZeneca seeks FDA approval of HUTCHMED lung cancer drug

ORPATHYS is being jointly ⁠developed by AstraZeneca and ​HUTCHMED and is commercialised by ​AstraZeneca....

AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

AstraZeneca seeks FDA approval for ORPATHYS-TAGRISSO combo to treat advanced lung cancer after EGFR-targeted treatment, showing improved survival.

AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination

Sept 29 (Reuters) - HUTCHMED (China) said on Tuesday that Anglo-Swedish drugmaker AstraZeneca had ​applied to the ‌US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with ‌advanced ​lung cancer. ORPATHYS...

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated ...

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after...